ArticleExploration (Beijing, China)2024
Targeted protein delivery based on stimuli-triggered nanomedicine.
Article in Exploration (Beijing, China), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Antimicrobial peptides for bacterial infections and their biomedical applications.Discover nano · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
- Smart nanoparticle delivery systems for curcumin: a targeted strategy to enhance anticancer efficacy and bioavailability.Journal of materials science. Materials in medicine · 2026Review
- pH-Activatable engineered nanoparticle-based selective hexokinase 2 degrader provokes GSDME-dependent pyroptosis for cancer therapy.Acta pharmaceutica Sinica. B · 2026Article
- Emerging Technologies and Integrated Interdisciplinary Strategies for Mitigating Protein Aggregation in Therapeutic Formulations.Pharmaceutical research · 2026Review
- Learn from nature: Biomimetic nanocarriers for intracellular protein delivery.Bioactive materials · 2026Review
- Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems.Drug delivery · 2025Review
- Site-specific adaptive nanovesicles for oral insulin delivery.Science advances · 2025Article
- Nano-oncology revisited: Insights on precise therapeutic advances and challenges in tumor.Fundamental research · 2025Review
- Dual-responsive and NIR-triggered detachable nanoplatform for integrated thrombolytic and antiplatelet therapy.Asian journal of pharmaceutical sciences · 2025Article
- Dual asparagine-depriving nanoparticles against solid tumors.Nature communications · 2025Article
- Nano-formulations in disease therapy: designs, advances, challenges, and future directions.Journal of nanobiotechnology · 2025Review
- Oral delivery of therapeutic proteins by engineered bacterial type zero secretion system.Nature communications · 2025Article
- Integrating synthetic polypeptides with innovative material forming techniques for advanced biomedical applications.Journal of nanobiotechnology · 2025Review
- Barcoded screening identifies nanocarriers for protein delivery to kidney.Nature communications · 2025Article
- EGCG and DOX dual-drug-loaded enzyme-responsive nanovesicles boost mitochondrial-mediated ICD for improved immunotherapy.Frontiers in pharmacology · 2025Article
- The Molecular Mechanisms of Natural Medicinal Active Ingredients Interfering with Male Fertility.Current pharmaceutical design · 2025Review
- Peptide nanozymes: An emerging direction for functional enzyme mimics.Bioactive materials · 2024Review
- ROS-sensitive PD-L1 siRNA cationic selenide nanogels for self-inhibition of autophagy and prevention of immune escape.Bioactive materials · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-based drugs have shown unique advantages to treat various diseases in recent years. However, most protein therapeutics in clinical use are limited to extracellular targets with low delivery efficiency. To realize targeted protein delivery, a series of stimuli-triggered nanoparticle formulations have been developed to improve delivery efficiency and reduce off-target release. These smart nanoparticles are designed to release cargo proteins in response to either internal or external stimuli at pathological tissues. In this way, varieties of protein-based drugs including antibodies, enzymes, and pro-apoptotic proteins can be effectively delivered to desired sites for the treatment of cancer, inflammation, metabolic diseases, and so on with minimal side effects. In this review, recent advances in the design of stimuli-triggered nanomedicine for targeted protein delivery in different biomedical applications will be discussed. A deeper understanding of these emerging strategies helps develop more efficient protein delivery systems for clinical use in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.